摘要
目的观察咪喹莫特联合伐昔洛韦治疗首诊为生殖器疱疹的临床疗效。方法 120例首诊为生殖器疱疹患者随机分成联合组60例和对照组60例,其中联合组外用5%咪喹莫特乳膏,3次/周,共8周,口服伐昔洛韦片0.3g,2次/d,共10d;对照组仅口服伐昔洛韦片,用法同治疗组;两组均于初始治疗后12周和24周观察生殖器疱疹的复发情况。结果 12周时,联合组复发率(16.67%)明显低于对照组(36.71%),两组差异有统计学意义(P<0.05);第24周时,两组复发率差异无统计学意义。结论联合外用咪喹莫特在发病初期可减少首诊为生殖器疱疹的复发,但远期疗效不显著。
Objective To observe the effect of topical imiquiomod combined with oral valaciclovir in the treatment of genital herpes. Methods One hundred and twenty patients with genital herpes were randomly assigned into two groups. Sixty patients in combination-therapy group received topical imiquiomod five percent cream 3 times a week for 8 weeks and oral valaciclovir 0.3 twice a day for 10 days. Sixty patients in the control group received oral valaciclovir only. The relapse of the patients in two groups was assessed at the week 12 and week 24 after the initial therapy. Results The recurrence rate of 16.67% was significantly lower in the combination treatment group than that in the control group with the recurrence rate of 36.71% at the week 12 after the treatment（ P 〈 0.05 ）. There was no significance of the recurrence rate in the two groups at the week 24. Conclusion Topical imiquiomod may benefit to decrease the relapse of genital herpes at early stage; however, its long-term efficacy is dissatisfied.
出处
《中国皮肤性病学杂志》
CAS
北大核心
2013年第3期277-278,共2页
The Chinese Journal of Dermatovenereology
关键词
生殖器疱疹
咪喹莫特
联合治疗
Genital herpes
Imiquiomod
Combination therapy
